Houston TX 黑色素瘤临床试验
61项针对 黑色素瘤的研究正在 Houston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
招募中
- M D Anderson Cancer Center, Houston
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
招募中观察性研究
- M D Anderson Cancer Center, Houston
BostonGene and Exigent Genomic INsight Study
招募中观察性研究
- Oncology Consultants, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
招募中
- M D Anderson Cancer Center, Houston
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
招募中3 期
- The University of Texas MD Anderson Cancer Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- UT MD Anderson Cancer Center, Houston
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
招募中1 期
- MD Anderson, Houston
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
招募中2 期
- University of Texas MD Anderson Cancer Center, Houston
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
招募中1/2 期
- M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
招募中1 期
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of BI 3810944 in Patients With Advanced Cancer
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
招募中2 期
- USA12-0, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
招募中1/2 期
- University of Texas-MD Anderson, Houston
- Lumi Research, Houston
Intratumoral N17350 in Advanced Solid Tumors
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
招募中1/2 期
- Research Site, Houston
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
招募中观察性研究
- M D Anderson Cancer Center, Houston
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
招募中1 期
- MD Anderson Cancer Center, Houston
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
招募中1 期
- M D Anderson Cancer Center, Houston
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
招募中1 期
- MD Anderson Cancer Center, Houston
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
招募中2 期
- MD Anderson Cancer Center, Houston
Pan-tumor MRD Study
招募中观察性研究
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
招募中2 期
- UT MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- MD Anderson Cancer Center, Houston
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
招募中1 期
- M D Anderson Cancer Center, Houston
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
招募中1 期
- MD Anderson, Houston
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
招募中1/2 期
- The University of Texas M. D. Anderson Cancer Center, Houston
Project: Every Child for Younger Patients With Cancer
招募中观察性研究
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
招募中观察性研究
- M D Anderson Cancer Center, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
招募中1/2 期
- Houston Methodist Hospital, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- The University of Texas, MD Anderson Cancer Center, Houston
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
招募中2 期
- M D Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
招募中2 期
- M D Anderson Cancer Center, Houston
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
招募中2 期
- M D Anderson Cancer Center, Houston
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
招募中1/2 期
- University of Texas MD Anderson Cancer Center, Houston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
招募中3 期
- Retina Consultants of Texas - (Houston), Houston
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
招募中观察性研究
- M D Anderson Cancer Center, Houston
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
招募中2 期
- M D Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
招募中
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study of VET3-TGI in Patients With Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
招募中2/3 期
- The University Of Texas Md Anderson Cancer Center, Houston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
招募中3 期
- Houston Methodist Hospital/Houston Methodist Cancer Center, Houston
ACTengine® IMA203 Combined With mRNA-4203
招募中1 期
- MD Anderson Cancer Center, Houston
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
招募中3 期
- The University of Texas M.D. Anderson Cancer Center, Houston
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Houston
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
招募中1/2 期
- Oncology Consultants, P.A., Houston
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of IBI363 in Subjects with Advanced Solid Malignancies
招募中2 期
- MD Anderson Cancer Center-University of Texas, Houston
- Oncology Consultants P.A., Houston
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
招募中
- The University of Texas MD Anderson Cancer Center, Houston
其他城市的 黑色素瘤试验
- New York City, NY41 项研究
- Nashville, TN34 项研究
- Los Angeles, CA34 项研究
- Pittsburgh, PA31 项研究
- Boston, MA25 项研究
- St. Louis, MO23 项研究
- Durham, NC22 项研究
- Philadelphia, PA22 项研究
- Tampa, FL21 项研究
- Columbus, OH21 项研究
- Dallas, TX21 项研究
- San Francisco, CA21 项研究
Houston的其他研究
- 非小细胞肺癌143 项研究
- 乳腺癌126 项研究
- 癌症（所有类型）124 项研究
- 结直肠癌101 项研究
- 转移性癌症100 项研究
- 卵巢癌90 项研究
- 急性髓系白血病88 项研究
- 肺癌78 项研究
- 前列腺癌73 项研究
- 子宫内膜癌69 项研究
- 胰腺癌59 项研究
- 头颈鳞状细胞癌49 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。